Loading viewer...
conference
Format: PDF conference
Pfizer's R&D leadership presents on the company's strong track record in drug approvals and robust clinical pipeline. The presentation highlights over 30 Phase 3 starts and 15 key approvals over six years, with approximately 50% of projects focused on biologics, biosimilars, and vaccines.
annual_report
42 Pages
conference
35 Pages
Credit Suisse
KPMG Cyber Security Readiness Ethiopia Roadshow 2022
conferenceconference
33 Pages
KPMG Advisory Services Limited
EPA 2024 Profiles in Leadership SmartWay Inaugural Webinar
conferenceconference
22 Pages
U.S. Environmental Protection Agency
Harvard Business School 2023 Leadership Development Capabilities
conferenceconference
61 Pages
Harvard Business School Publishing